Oral Contraceptive Consumption and Cerebral Venous sinuses Thrombosis

  • Kukum Jha Gupta Tribhuvan University Teaching Hospital . Maharajganj, Kathmandu , Nepal.

Abstract

Introduction: Cerebral venous sinus thrombosis (CVST) is a rare cause of stroke and the clinical presentation is variable. One of the more common acquired risk factors of venous sinus thrombosis is oral contraceptive medications. While the prognosis for CVST is favorable, it is important to identify and treat early to prevent neurologic deficits. CVST accounts for 0.5% of strokes and most commonly presents with headaches and in many cases focal neurologic deficits. Diagnosis is confirmed with neuroimaging including CT angiography or MR angiography. Treatment consists of anticoagulation and in some cases, thrombolytic therapy is beneficial. The overall prognosis of CVST is favorable.The objective of the study is to describe the features of a series of patient with CVST due to consumption of OCPs, treated in the department of Neurosurgery, Bir hospital and OM hospital, and to discuss the risk factors associated with consumption of OCPs, its presentation, and outcome.Methods: This is a retrospective case series carried out in the department of Neurosurgery, Bir hospital and OM hospital during the year September 2012 to September 2014. Demographic features like age, presenting symptoms, clinical findings and outcome were analyzed. All cases received heparin or LMWH followed by Warfarin.Results: Nine patients were identified over a period of 2 years. The presenting symptoms included headache, vomiting, loss of consciousness, focal neurological deficit, seizure and neck pain. Signs found included papilloedema, fever, slurring of speech and focal neurological signs.Conclusion: Dural sinus thrombosis is a rare and under-recognized cause of headache that should be considered in women with recent introduction of hormonal contraception. The absence of papilledema and a negative CT brain should not halt further workup. MRI/venogram is mandatory to confirm the diagnosis.

Author Biography

Kukum Jha Gupta, Tribhuvan University Teaching Hospital . Maharajganj, Kathmandu , Nepal.
Department of Surgery Institute of Medicine,

References

1. Benamer HTS, Bone I. Cerebral venous thrombosis: anticoagulants or thrombolytic therapy?. Journal of Neurology Neurosurgery & Psychiatry 2000;69:427–430
2. Chow K, Gobin YP, Saver J, Kidwell C, Dong P, Viñuela F. Endovascular treatment of dural sinus thrombosis with rheolytic thrombectomy and intra-arterial thrombolysis. Stroke 2000;3:1420–1425.
3. Bousser MG. Cerebral venous thrombosis: nothing, heparin, or local thrombolysis? Stroke 1999; 30:481–483.
4. Cantu´ C, Barinagarrementeria F. Cerebral venous thrombosis associated with pregnancy and puerperium. Review of 67 cases. Stroke 1993; 24: 1880–1884.
5. Lanska DJ, Kryscio RJ. Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke 2000; 31:1274–1282.
6. Vessey MP. Thrombosis and the pill. Prescr J 1970; 10:1–7.
7. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346:1589–1593.
8. [No authors listed]. Effect of different progestagens in low dose oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346:1582–1588.
9. Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, Tans G, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84:4–8.
10. Chasen-Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998; 128:467–477.
11. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344:1453–1457.
12. Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313:1127–1130.
13. De Brujin SF, Stam J, Koopman MM, Vendenbroucke JP. Case–control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. BMJ 1998; 316:589–592.
14. WHO. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use. Geneva: World Health Organization1996.pp.13–26.
15. Vogl TJ, Bergman C, Villringer A, Einha¨upl K, Lissner J, Felix R. Dural sinus thrombosis: value of venous MR angiography for diagnosis and follow-up. Am J Roentgenol 1994; 162:1191–1198.
16. Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin 1992; 10: 87–111.
Published
2016-03-05
How to Cite
JHA GUPTA, Kukum. Oral Contraceptive Consumption and Cerebral Venous sinuses Thrombosis. J Soc Surg Nep, [S.l.], v. 17, n. 1, mar. 2016. ISSN 2392-4772. Available at: <https://www.jssn.org.np/index.php?journal=jssn&page=article&op=view&path%5B%5D=http%3A%2F%2Fdx.doi.org%2F10.3126%2Fjssn.v17i1.15173>. Date accessed: 05 oct. 2024.
Section
Original Article

Keywords

Cerebral Venous sinus Thrombosis (CVST), Heparin, OCP (Oral Contraceptive pills)